Cerenis Therapeutics, Inc. to Present Clinical Proof-of-Concept Results for CER-627 program (niacin/aspirin combinations) at the European Atherosclerosis Society Congress June 20-23

TOULOUSE, France & ANN ARBOR, Mich.--(BUSINESS WIRE)--Cerenis Therapeutics SA (Cerenis), a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.